Eyenovia, Inc. (NASDAQ:EYEN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET

Company Participants

Eric Ribner - Investor Relations

Sean Ianchulev - President, Chief Executive Officer & Chief Medical Officer

Michael Rowe - Chief Operating Officer

John Gandolfo - Chief Financial Officer

Conference Call Participants

Tim Chiang - Northland Capital

Operator

Thank you for standing by, and welcome to the Eyenovia First Quarter 2022 Earnings Call. During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded, Thursday, May 12, 2022.

I would now like to turn the conference over to Eric Ribner with LifeSci Advisors. Please go ahead.

Eric Ribner

Good afternoon, and welcome to Eyenovia's first quarter 2022 earnings conference call and audio webcast. With me today are Eyenovia’s Chairman, Chief Executive and Chief Medical Officer, Dr. Sean Ianchulev, Chief Operating Officer, Michael Rowe, and Chief Financial Officer, John Gandolfo. This afternoon, Eyenovia issued a press release announcing financial results for three months ended March 31, 2022. We encourage everyone to read today's release as well as Eyenovia's annual report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 30, 2022. The company's press release and annual report are also available on Eyenovia's website at eyenovia.com. In addition, this conference call is being webcast through the company's website and will be archived for future reference.

Please note, on today's call, we will be discussing investigational product candidates, which have yet to receive FDA approval. Please also note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act.

We caution listeners that during this call, Eyenovia’s management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. This forward-looking statement -- these forward-looking statements are subject to a number of risks, which are described in more detail in our annual report on Form 10-K and most recent refiled 10-Q. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 12, 2022. Eyenovia undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws.